Scientific article
OA Policy
English

Riociguat for pulmonary arterial hypertension associated with congenital heart disease

Published inHeart, vol. 101, no. 22, p. 1792-1799
Publication date2015
Abstract

The Pulmonary Arterial hyperTENsion sGC-stimulator Trial-1 (PATENT-1) was a randomised, double-blind, placebo-controlled phase III trial evaluating riociguat in patients with pulmonary arterial hypertension (PAH). PATENT-2 was an open-label long-term extension to PATENT-1. Here, we explore the efficacy and safety of riociguat in the subgroup of patients with persistent/recurrent PAH after correction of congenital heart disease (PAH-CHD) from the PATENT studies.

Citation (ISO format)
ROSENKRANZ, Stephan et al. Riociguat for pulmonary arterial hypertension associated with congenital heart disease. In: Heart, 2015, vol. 101, n° 22, p. 1792–1799. doi: 10.1136/heartjnl-2015-307832
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
Journal ISSN1468-201X
506views
470downloads

Technical informations

Creation17/09/2015 12:52:00
First validation17/09/2015 12:52:00
Update time14/03/2023 23:44:32
Status update14/03/2023 23:44:32
Last indexation31/10/2024 01:38:40
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack